A Phase II study of capecitabine plus cisplatin (plustrastuzumab) for previously untreated advanced gastric cancer.
Phase 2
- Conditions
- untreated advanced gastric cancer
- Registration Number
- JPRN-UMIN000006458
- Lead Sponsor
- Ehime University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
1)Severe hypersensitivity to have a history fluorouracil,platinum,trastuzumab 2)Senere renal failure 3)Within seven days stop S-1(tegaful gimerasil oterasil)treatment 4)Intend to make pregnant 5)Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ORR:Overall ResponseRate
- Secondary Outcome Measures
Name Time Method